IPF
Boehringer’s OFEV slows IPF disease progression by half in trials
February 26, 2016Research and Development, Sales and Marketing Boehringer Ingelheim, IPF, ofev
Boehringer Ingelheim has revealed pooled analysis data from three trials, showing that its drug OFEV significantly reduces the risk of …
Gilead terminates Phase II simtuzumab IPF study
January 6, 2016Research and Development Gilead, IPF, idiopathic pulmonary fibrosis, simtuzumab
Gilead Sciences has announced the termination of its Phase II clinical study of the investigational monoclonal antibody simtuzumab in patients …
Boehringer earns NICE nod for IPF drug Ofev
September 14, 2015Sales and Marketing Boehringer Ingelheim, IPF, NICE, idiopathic pulmonary fibrosis
NICE has recommended Boehringer Ingelheim’s Ofev as a treatment for idiopathic pulmonary fibrosis after the German firm agreed to a …
Boehringer’s beer breach at German congress
February 20, 2015Medical Communications, Sales and Marketing ABPI, Boehringer, ERS, IPF, PMCPA, breach, code, munich
A complaint made by a pulmonologist against the competence of Boehringer Ingelheim speakers during a congress held in Germany last …
Boehringer gains EU approval for Ofev
January 19, 2015Sales and Marketing Boehringer, Esbriet, IPF, InterMune, ingelheim, nintedanib, ofev
The European Commission has approved Boehringer Ingelheim’s Ofev as a treatment for idiopathic pulmonary fibrosis (IPF). The approval follows the …
Roche buys Ariosa Diagnostics
December 2, 2014Research and Development, Sales and Marketing IPF, IQuum, InterMune, Roche, ariosa, cfdna, diabetes, genia, seragon
Roche has purchased the privately-held US company Ariosa Diagnostics for an undisclosed fee as it looks to expand further into …
Boehringer’s lung cancer drug Vargatef sees EU approval
November 28, 2014Sales and Marketing Boehringer, EU, Europe, IPF, NSCLC, lung cancer, nintedanib, ofev, vargatef
Boehringer Ingelheim’s nintedanib has received its second nod in Europe this month with the European Commission approving it for the …
Growing IPF drugs market evident at ERS Congress
November 3, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ERS, Esbriet, IPF, elf, european respiratory society, ofev
Arriving in Germany for this year’s European Respiratory Society (ERS) International Congress 2014, what awaited Pharmafile at the Ausgang was …
Boehringer seeks more indications for IPF drug
October 22, 2014Research and Development, Sales and Marketing Boehringer, IPF, NSCLC, colectoral, crc, nintedanib, ofev
Boehringer Ingelheim’s nintedanib has entered Phase III studies for the treatment of colorectal cancer (CRC), which could add to the …
Boehringer and Roche IPF drugs win FDA approval
October 16, 2014Research and Development, Sales and Marketing Boehringer, ERS, Esbriet, FDA, IPF, InterMune, Roche, US, lung scarring, lungs, ofev
The FDA has approved both Roche’s Esbriet (pirfenidone) and Boehringer Ingelheim’s Ofev (nintedanib) for the treatment of the fatal lung …
Boehringer’s lung cancer drug gets EMA nod
September 29, 2014Sales and Marketing Boehringer, IPF, docetaxel, ingelheim, lung cancer, nintedanib
The EMA has issued a positive opinion for the approval of Boehringer Ingelheim’s nintedanib in combination with docetaxel for the …
InterMune’s IPF drug shines at ERS Congress
September 10, 2014Research and Development, Sales and Marketing Boehringer, ERS, Esbriet, IPF, InterMune, idiopathic pulmonary fibrosis, munich, pirfenidone
InterMune has posted positive data for its lung-scarring drug at this year’s European Respiratory Society Annual Congress 2014 (ERS). Pharmafile …
Roche pays $8.3bn for InterMune
August 26, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cancer, Genentech, IPF, Illumina, InterMune, Roche
Roche has stumped up $8.3 billion in cash to pay for US biotech firm InterMune and will gain access to …
InterMune stock jumps on suitor claims
August 14, 2014Sales and Marketing Boehringer, Esbriet, FDA, GSK, IPF, InterMune
Riding high of the success of its new lung drug Esbriet, InterMune has become the focus of some serious takeover …
IPF grabs headlines at American Thoracic Society conference
July 21, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing IPF, ats, ats 2014, brett wells, idiopathic pulmonary fibrosis, san diego, thoracic society
Just prior to landing in San Diego it was somewhat disconcerting to see fire spreading across the terrain and huge …
Latest content
